Product Information
ENTECAVIR 0.5 MG TABLET is a generic product labeled by Solco Healthcare US LLC, priced at $0.2186 per EA under NDC 43547043603. Its NADAC has been published 423 times since Aug 29, 2018.
FDA first approved this application on Oct 10, 2017.
Strength
.5 mg/1
Manufacturer
Solco Healthcare US LLCNDC
43547043603
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ENTECAVIR ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA208782FDA Approved
10/10/2017
On Market Since
4/1/2018
Pharmacological Classes
Price Statistics
The NADAC for ENTECAVIR 0.5 MG TABLET has been published 423 times since Aug 29, 2018, and over the history we have for it it has declined 90.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2186 per EA |
|---|---|
| All-time high | $2.7071 (Nov 14, 2018) |
| All-time low | $0.2096 (May 20, 2026) |
| 52-week high | $0.2640 |
| 52-week low | $0.2096 |
| Median price | $0.7225 |
| Average price | $0.8633 |
| Largest weekly change | +48.1% (Jul 17, 2024) |
| Weeks tracked | 423 |
| Tracking since | Aug 29, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solco Healthcare US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ENTECAVIR market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ENTECAVIR 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ENTECAVIR 0.5 MG TABLET, manufactured by Solco Healthcare US LLC, is $0.2186 per EA (NDC 43547043603), effective Sep 30, 2026.
How has the price of ENTECAVIR 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ENTECAVIR 0.5 MG TABLET has declined 90.7%. It has been tracked across 423 weekly CMS publications since Aug 29, 2018.
What are the highest and lowest recorded NADAC prices for ENTECAVIR 0.5 MG TABLET?
Since Aug 29, 2018, the NADAC for ENTECAVIR 0.5 MG TABLET has ranged from a low of $0.2096 (May 20, 2026) to a high of $2.7071 (Nov 14, 2018), with a median of $0.7225 per EA.
Are there cheaper alternatives to ENTECAVIR 0.5 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ENTECAVIR 0.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ENTECAVIR 0.5 MG TABLET?
ENTECAVIR 0.5 MG TABLET (NDC 43547043603) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.